Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT01342081 Completed - Ocular Hypertension Clinical Trials

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Start date: May 2011
Phase: Phase 3
Study type: Interventional

DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used concomitantly, in IOP(intraocular pressure) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a multicenter, randomized, double-masked, parallel-group comparison study. Safety will be compared and evaluated as well.

NCT ID: NCT01340014 Completed - Ocular Hypertension Clinical Trials

Patient Preference Comparison of AZARGA Versus COSOPT

Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess patient preference regarding ocular comfort of AZARGA® compared to COSOPT® after one week instillation of each study medication.

NCT ID: NCT01336569 Completed - Glaucoma Clinical Trials

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

Start date: February 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01330979 Completed - Ocular Hypertension Clinical Trials

24-hour Efficacy of AR-12286

Start date: May 2011
Phase: Phase 2
Study type: Interventional

An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension

NCT ID: NCT01327599 Completed - Ocular Hypertension Clinical Trials

Efficacy of Changing to DUOTRAV® From Prior Therapy

Start date: August 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess the efficacy and tolerability of changing to DUOTRAV® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having uncontrolled intraocular pressure (IOP).

NCT ID: NCT01318252 Completed - Clinical trials for Ocular Hypertension (OHT)

AL-54478 Proof of Concept Study

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01312454 Terminated - Ocular Hypertension Clinical Trials

Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the safety and efficacy of AL-59412C injected intravitreally relative to Vehicle.

NCT ID: NCT01310777 Completed - Ocular Hypertension Clinical Trials

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01309204 Completed - Ocular Hypertension Clinical Trials

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine fixed combination in lowering intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly (Brinzolamide+Brimonidine) in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01306461 Completed - Ocular Hypertension Clinical Trials

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

Start date: March 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol. This study will enroll patients who have ocular hypertension or glaucoma. The study schedule includes seven visits to the study site and three stages: - washout of 5 days to 4 weeks depending on current glaucoma medication (if any) - 6-month study treatment period - 1-3 weeks post-study period